KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to -$2.2 million.

  • Biomarin Pharmaceutical's Cash from Financing Activities rose 9956.54% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.7 million, marking a year-over-year increase of 9176.57%. This contributed to the annual value of -$526.4 million for FY2024, which is 271116.57% down from last year.
  • Biomarin Pharmaceutical's Cash from Financing Activities amounted to -$2.2 million in Q3 2025, which was up 9956.54% from -$4.6 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Cash from Financing Activities ranged from a high of $14.4 million in Q4 2021 and a low of -$499.1 million during Q3 2024
  • For the 5-year period, Biomarin Pharmaceutical's Cash from Financing Activities averaged around -$32.1 million, with its median value being -$1.0 million (2021).
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Cash from Financing Activities skyrocketed by 83142.58% in 2022, and later plummeted by 6324073.6% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Cash from Financing Activities (Quarter) stood at $14.4 million in 2021, then decreased by 24.5% to $10.9 million in 2022, then fell by 0.27% to $10.8 million in 2023, then crashed by 73.63% to $2.9 million in 2024, then plummeted by 175.87% to -$2.2 million in 2025.
  • Its last three reported values are -$2.2 million in Q3 2025, -$4.6 million for Q2 2025, and -$38.8 million during Q1 2025.